Welcome to the
European Biotechnology Network!
The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe.
The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.
Catch of the day
LSP raises €112m10.03.2014 Life Sciences Partners (LSP) closed its Health Economics Fund (HEF) at €112m, exceeding its target of €100m.Catch of the Day is brought to you by European Biotechnology News
The Amsterdam-headquartered investor's first investment from the new fund was lluminOss Medical, a US company commercialising an innovative, minimally invasive and cost-saving approach to orthopaedic implants for the treatment of bone fractures. According to LSP, HEF aims at investing in European and Northern American healthcare companies in the areas of medical technology, diagnostics and eHealth, provided their products or technologies have the potential to improve the quality of healthcare and reduce its cost simultaneously. "The concept of sustainable health care is very attractive to investors who expect a socio-economic return next to a financial return," said Rudy Dekeyser, managing partner of LSP HEF. "In parallel with the fundraising, we have built a rich portfolio of interesting investment dossiers and expect to make several more investments in the coming months."
The focus of the Amsterdam-based investor is on later stage private companies with products on the market or close to market introduction. LSP has already raised over €700m ($960m) in funds and built a strong portfolio of companies with high exit potential that includes Prosensa, Celladon, Probiogen and Merus. Most recently, vaccine developer Okairos AG was acquired by GlaxoSmithKline in a US$250m deal. "We are delighted to have Dutch, German and French health insurance companies as LPs, next to a number of top quality family offices and asset managers," commented René Kuijten, general partner LSP.
Our Corporate Members are
European Biotechnology Network
Avenue de Tervueren 13
1040 Brussels, Belgium
Tel: +32 27 33 72 37